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Background-—Evidence largely from animal studies suggests that conjugated linoleic acid (CLA) may have cardiovascular health
beneﬁts. However, few prospective studies have examined the association between CLA and cardiovascular disease. We have
prospectively examined the association between serum CLA and incident coronary heart disease and heart failure (HF) in older
men.
Methods and Results-—Prospective study of 3806 men, aged 60 to 79 years, without prevalent HF followed up for an average of
13 years, during which there were 295 incident HF cases. A high-throughput serum nuclear magnetic resonance metabolomics
platform was used to measure CLA concentration in serum, expressed as a percentage of total fatty acids (CLA%). CLA% was
adversely associated with cholesterol and high-density lipoprotein cholesterol but was inversely associated with C-reactive protein
and NT-proBNP (N-terminal pro-B-type natriuretic peptide; a marker of ventricular stress). No association was seen between CLA%
and incident coronary heart disease. High CLA% was associated with signiﬁcantly reduced risk of HF after adjustment for HF risk
factors and C-reactive protein (hazard ratio [95% conﬁdence interval], 0.64 [0.43–0.96]; quartile 4 versus quartile 1). Elevated
CLA% was associated with reduced HF risk only in those with higher dairy fat intake, a major dietary source of CLA (test for
interaction P=0.03). The reduced risk of HF was partially explained by NT-proBNP. High dairy fat intake was not associated with
incident coronary heart disease but was associated with reduced risk of HF, largely because of the inverse effect of CLA.
Conclusions-—The ﬁnding that high CLA% is associated with lower risk of incident HF in older men requires conﬁrmation in larger
studies. ( J Am Heart Assoc. 2018;7:e006653. DOI: 10.1161/JAHA.117.006653.)
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C onjugated linoleic acid (CLA) is a trans fatty acid (TFA)that naturally occurs as a mixture of positional and
geometric isomers of LA. The amount of CLA in the human
body seems to be directly related to the dietary intake of
CLA.1 CLA is produced naturally in ruminant animals, such as
cows, sheep, and goats. Dairy products are a primary source
of cis-9, trans-11-CLA (c9,t11-CLA), the most prevalent CLA
isomer, in the diet of humans.1–3 Epidemiological studies have
shown a strong positive association between the intake of
TFAs and coronary heart disease (CHD).4,5 However, evidence
largely based on animal models has paradoxically shown CLA
to have antiatherosclerotic, antidiabetic, anti-inﬂammatory,
and immune-modulating properties.1–3,6,7 In vitro and in vivo
studies in rats have also shown CLA to suppress cardiac
hypertrophy, a major risk factor for heart failure (HF).8 CLA
has gained an increasing amount of attention in the past
decade because of its potential health beneﬁt1 and in the
potential for naturally increasing the isomer c9,t11-CLA
content of milk and dairy products.2 However, in human
studies, evidence on the antiatherosclerotic effects of CLA
remains contradictory.6,7,9–13 There is a paucity of prospec-
tive studies on CLA and incident cardiovascular disease
(CVD), but one study has shown higher CLA levels measured
in adipose tissue to be associated with lower risk of
myocardial infarction (MI).14 However, to date, no prospective
studies have examined the association between CLA and
incident HF. To further understand the cardiovascular health
implications of CLA, we have examined the association
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between serum CLA and the following: (1) vascular risk
factors, (2) incident CHD, and (3) incident HF in older men.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
The British Regional Heart Study is a prospective study
involving 7735 men, aged 40 to 59 years, drawn from one
general practice in each of 24 British towns, who were
screened between 1978 and 1980.15 The population studied
was socioeconomically representative of British men and
comprises predominantly white Europeans (>99%). From
1998 to 2000, all surviving men, now aged 60 to 79 years,
were invited for a 20th year follow-up examination. Ethical
approval has been obtained from all relevant local research
ethics committees. All participants provided informed written
consent to the investigation, which was performed in
accordance with the Declaration of Helsinki. All men
completed a mailed questionnaire, providing information on
their lifestyle and medical history, had a physical examination,
and provided a fasting blood sample. The samples were frozen
and stored at 20°C on the day of collection and transferred
in batches for storage at 70°C until analysis. Details of their
medications were recorded at the examination. Twelve-lead
ECGs were recorded using a Siemens Sicard 460 instrument
and were analyzed using Minnesota Coding deﬁnitions at the
University of Glasgow ECG core laboratory. A total of 4252
men (77% of survivors) attended for examination. Blood
measurements were available in 4049 men. We excluded 119
men with a history of HF, leaving 3930 men for analyses. The
1998 to 2000 examination served as the baseline for the
current analyses.
Cardiovascular Risk Factors
Details of measurement and classiﬁcation methods for body
mass index, smoking status, physical activity, social class,
alcohol intake, blood pressure, blood lipids, plasma glucose,
renal dysfunction, and forced expiratory volume in 1 second
in this cohort have been described.16–18 Prevalent diabetes
mellitus included men with a diagnosis of diabetes mellitus
and men with a fasting blood glucose level ≥7 mmol/L. NT-
proBNP (N-terminal pro-B-type natriuretic peptide) was
determined using the Elecsys 2010 (Roche Diagnostics,
Burgess Hill, UK).17 Troponin T was measured by a high-
sensitivity method on an e411 (Roche Diagnostics) using
the manufacturer’s calibrators and quality control material.
C-reactive protein (CRP) was assayed by ultrasensitive
nephelometry (Dade Behring, Milton Keynes, UK). Electro-
cardiographic left ventricular hypertrophy was deﬁned
according to relevant Minnesota code (code 3.1 or 3.3).
Atrial ﬁbrillation was deﬁned according to Minnesota codes
8.3.1 and 8.3.3.
Dietary Assessment
Dietary intake was measured at baseline from 1998 to 2000
with a self-administered food frequency questionnaire (FFQ)
that was developed for use in the World Health Organization’s
Monitoring Trends and Determinants in Cardiovascular
Disease Survey.19 Participants reported how frequently they
usually ate 86 different food and drink items per week. Total
macronutrient and micronutrient intakes of foods consumed
were derived using a validated computer program to calculate
the total nutrient composition of all foods reported as
consumed in the FFQ. The FFQ used in this study has
conﬁrmed the known protective effect of the Mediterranean
diet on CVD risk,20 providing evidence of the validity of the
FFQ. On the basis of reported milk and butter intake, the men
were divided into 4 groups of dairy fat intake: 1 (low),
skimmed/semiskimmed milk and low-fat cheese; 2, skimmed
milk and full-fat cheese or full-fat milk and low-fat cheese;
Clinical Perspective
What Is New?
• Conjugated linoleic acid (CLA) is a trans fatty acid that has
been shown in clinical studies to have antiatherosclerotic,
antidiabetic, anti-inﬂammatory, and immune-modulating
properties.
• This is the ﬁrst prospective study on the association
between CLA and risk of incident heart failure (HF).
• CLA expressed as a percentage of total fatty acids
was inversely associated with inﬂammation and NT-proBNP
(N-terminal pro-B-type natriuretic peptide), a marker of
neurohormonal activation and cardiac injury.
• High CLA expressed as a percentage of total fatty acids was
associated with signiﬁcantly reduced risk of incident HF (but
not coronary heart disease) after adjustment for established
risk factors for HF.
What Are the Clinical Implications?
• The novel ﬁnding of an inverse association between CLA
expressed as a percentage of total fatty acids and HF
requires conﬁrmation in other populations.
• The observational data suggest that a diet rich in CLA may
be protective against the development of HF and may have
important implications for effective nutritional interventions
towards the prevention of HF.
• Primary intervention trials in older people at risk of HF
would be needed to conﬁrm whether increasing CLA
through supplements or diet would reduce risk of HF.
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3, semiskimmed milk and full-fat cheese; and 4 (high), full-fat
milk and high-fat cheese.
CLA and Other Fatty Acids
A high-throughput serum nuclear magnetic resonance (NMR)
metabolomics platform was used to quantify >200 metabolite
measures from unthawed serum samples that represent a
broad molecular signature of systemic metabolism.21 The
metabolites were measured in a single experimental setup
that allows for the simultaneous quantiﬁcation of routine
lipids, total lipid concentrations of 14 lipoprotein subclasses,
fatty acid composition (including monounsaturated fatty acids
[MUFAs], saturated fatty acids), and polyunsaturated fatty
acids [PUFAs]), CLA, various glycolysis precursors, ketone
bodies, and amino acids in absolute concentration units.21,22
Applications of this high-throughput metabolomics platform
have previously been applied in both epidemiological and
genetics studies,22 and details of the experimentation have
been described elsewhere.21,22 The quantiﬁcation of fatty acid
biomarkers using the NMR approach has been validated by
comparing NMR with gas chromatography in the Cardiovas-
cular Risk in the Young Finn Study The fatty acids quantiﬁ-
cation was highly consistent between methods (r=0.92 for
MUFA%, and r=0.94 for PUFA%), although CLA expressed as a
percentage of total fatty acids (CLA%) was not speciﬁcally
validated in this study.23 CLAs, PUFAs, saturated fatty acids,
and MUFAs were expressed as a percentage of total fatty
acids (CLA%, PUFA%, saturated fatty acid %, and MUFA%,
respectively). CLA% was available in 3806 men.
Follow-Up
All men have been followed up from initial examination (1978–
1980) to June 2012 for cardiovascular morbidity and mortality
through general practitioners’medical records and the National
Health Service Register for mortality. Follow-up has been
achieved for 99% of the cohort.15 Fatal CHD events were
deﬁned as death with CHD (International Classiﬁcation of
Diseases, Ninth Revision [ICD-9] codes 410–414) as the
underlying code. Evidence of nonfatal MI and HF was obtained
by regular biennial reviews of participants’ primary care records
(including hospital and clinic correspondence) through to the
end of the study period. A nonfatal MI was diagnosed according
to World Health Organization criteria. Incident nonfatal HF was
based on a physician diagnosis of HF recorded in primary care
records and veriﬁed using details of available clinical informa-
tion from primary and secondary care records (including
symptoms, signs, investigations, and treatment response) to
ensure consistency with current diagnostic practice24; any
cases with a strong likelihood of alternative diagnoses were
excluded from considerations. Fatal HF cases were those in
which the diagnosis of HF was mentioned as the underlying
cause of death (ICD-9 code 428). Incident HF included both
incident nonfatal HF and fatal HF cases.
Statistical Analyses
The men were divided into equal quartiles on the basis of the
CLA% distribution. Tests for trend across the 4 CLA% groups
were performed using the v2 linear test for trend across the 4
groups for categorical variables and ANOVA for continuous
variables. Cox proportional hazards model was used to assess
the multivariate-adjusted hazard ratios (relative risk) by quar-
tiles of CLA%. In multivariate analyses, smoking (never, long-
term ex-smokers [>15 years], recent ex-smokers [<15 years],
and current smokers), social class (manual versus nonmanual),
physical activity (4 groups), prevalent diabetes mellitus (yes/
no), prevalent MI (yes/no), use of antihypertensive treatment
(yes/no), left ventricular hypertrophy (yes/no), renal dysfunc-
tion (yes/no), and atrial ﬁbrillation (yes/no) were ﬁtted as
categorical variables. Systolic blood pressure, bodymass index,
high-density lipoprotein cholesterol, estimated glomerular
ﬁltration rate, CRP, PUFA%, and NT-proBNP were ﬁtted
continuously. Subsidiary analysis was stratiﬁed by men with
and without previous MI. Analyses were also performed by
stratifying the men by high and low NT-proBNP level and
by dairy fat intake groups. Test for interactionwas performed by
including an interaction term, CLA%9dairy fat intake groups
(NT-proBNP groups), with CLA% ﬁtted continuously.
Results
During the mean follow-up of 13 years from 1998 to 2000 to
July 2012, there were 295 incident HF cases and 413 major
CHD events in the 3806 men with no diagnosed HF. The mean
(SD) CLA% level in this study population was 0.38 (0.17).
CLA and Vascular Risk Factors
Table 1 shows baseline characteristics in the study popula-
tion by quartiles of CLA%. Those with high circulating CLA%
tended to be older, more inactive, and heavier drinkers and
had a higher body mass index, but they showed a lower
prevalence of MI, atrial ﬁbrillation, and use of antihypertensive
treatment than those with lower CLA%. CLA% related to
saturated dairy fat intake and frequency of beef and lamb
intake and was signiﬁcantly associated with increased dietary
total fat (g/d) and saturated fat intake (g/d). CLA% related
positively to saturated fatty acid % and MUFA% but inversely
to PUFA%. Elevated CLA% was associated with lower high-
density lipoprotein cholesterol, higher total cholesterol, and
higher systolic blood pressure but was inversely associated
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with CRP and NT-proBNP (but not cardiac troponin T). CLA%
remained adversely associated with blood lipids and blood
pressure and inversely associated with CRP and NT-proBNP
after adjustment for age and body mass index and on
exclusion of men with prevalent MI (Table 2).
CLA, Dairy Fat Intake, and Major CHD
CLA% did not relate to major CHD events. The age-adjusted
risks of CHD in all men for the 4 quartiles of CLA% were 1.00,
0.95 (0.72–1.26), 0.93 (0.71–1.24), and 1.13 (0.86–1.47).
Table 1. Baseline Characteristics by Quartiles of Serum CLA% in 3890 Men Without HF
Characteristics
CLA% (Quartiles)
P Value for Trend
1 2 3 4
(n=915) (n=960) (n=971) (n=960)
(<0.26) (0.26–0.35) (0.36–0.46) (≥0.47)
Age, y 68.5 68.4 68.7 69.0 0.04
BMI, kg/m2 26.3 27.0 27.0 27.0 <0.0001
Smokers, % 12.5 11.9 12.0 14.4 0.22
Manual, % 56.2 55.7 50.3 52.0 0.01
Inactive, % 32.3 32.2 34.8 36.7 0.02
Heavy drinkers, % 2.9 3.8 3.5 4.9 0.04
Myocardial infarction, % 10.4 12.2 9.2 8.1 0.02
Diabetes mellitus, % 6.7 7.0 9.2 8.1 0.56
LVH, % 8.7 7.6 6.9 7.3 0.48
AF, % 4.6 3.3 3.6 2.1 0.005
Renal dysfunction, % 14.4 14.8 17.2 14.9 0.45
Use of antihypertensive drugs, % 33.5 35.4 31.5 29.8 0.02
Dietary intake (FFQ)
Beef >2 times/wk, % 32.9 37.6 41.0 44.1 <0.0001
Lamb >2 times/wk, % 7.5 8.9 11.7 16.2 <0.0001
High dairy fat, % 7.4 13.4 16.4 21.6 <0.0001
Total fat, g/d 66.923.9 68.725.1 72.025.7 79.828.2 <0.0001
Total energy, kcal 2056495 2076522 2130533 2200542 <0.0001
Serum fatty acids
PUFA% 39.0 (3.30) 37.2 (3.33) 36.1 (3.23) 37.8 (3.62) <0.0001
MUFA% 24.5 (3.25) 26.1 (3.31) 27.0 (3.25) 28.7 (3.49) <0.0001
SFA% 36.5 (1.61) 36.7 (1.57) 36.9 (1.49) 37.6 (1.82) <0.0001
Biological factors
SBP, mm Hg 148.2 (23.8) 148.3 (24.0) 150.2 (24.2) 150.8 (23.7) 0.005
Cholesterol, mmol/L 5.73 (0.98) 6.00 (1.05) 6.10 (1.09) 6.25 (1.11) <0.0001
HDL-C, mmol/L 1.36 (0.35) 1.33 (0.35) 1.31 (0.32) 1.29 (0.34) <0.0001
Glucose, mmol/L* 5.81 (5.22–6.04) 5.87 (5.26–6.12) 5.81 (5.25–6.06) 5.93 (5.32–6.19) 0.05
FEV1, L 2.59 (0.69) 2.64 (0.65) 2.63 (0.65) 2.56 (0.64) 0.21
CRP, mg/L* 1.84 (0.80–3.93) 1.67 (0.82–3.12) 1.67 (0.81–3.38) 1.68 (0.83–3.35) 0.08
cTnT, pg/mL* 11.94 (8.90–15.80) 11.58 (8.60–15.70) 11.94 (8.70–15.70) 12.06 (9.0–16.5) 0.34
NT-proBNP, pg/mL* 104.6 (47–194) 100.5 (49–199) 94.6 (45–190) 89.2 (43–178) 0.002
Data are given as mean (SD unless otherwise speciﬁed. AF indicates atrial ﬁbrillation; BMI, body mass index; CLA%, conjugated linoleic acid expressed as a percentage of total fatty acids;
CRP, C-reactive protein; cTnT, cardiac troponin T; FEV1, forced expiratory volume in 1 second; FFQ, food frequency questionnaire; HDL-C, high-density lipoprotein cholesterol; HF, heart
failure; LVH, left ventricular hypertrophy; MUFA%, monounsaturated fatty acid expressed as a percentage of total fatty acids; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PUFA%,
polyunsaturated fatty acid expressed as a percentage of total fatty acids; SBP, systolic blood pressure; and SFA%, saturated fatty acid expressed as a percentage of total fatty acids.
*Data are given as geometric mean (interquartile range).
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Similarly, dairy fat intake was not associated with major CHD
events. The age-adjusted relative risks were 1.00, 0.90 (0.59–
1.38), 0.94 (0.71–1.25), and 1.06 (0.77–1.46). Exclusion of
men with MI made little difference to these ﬁndings.
CLA, Dairy Fat Intake, and Incident HF
CLA% was inversely associated with HF after adjustment for
CVD risk factors and PUFA (model 2; Table 3). However,
further adjustment for NT-proBNP attenuated the association.
The reduced risk of HF associated with elevated CLA% was
seen in both men with and without MI (Table 3). When
stratiﬁed by levels of NT-proBNP, the reduced risk of HF
associated with elevated CLA% was seen in both men with
high (≥188 pg/mL; top quartile) levels of NT-proBNP and
those with levels <188 pg/mL. The adjusted hazard ratios
(95% conﬁdence interval) (top quartile versus bottom quartile)
were 0.67 (0.42–1.09) and 0.59 (0.35–1.01), respectively.
There was no evidence of an interaction between CLA% and
NT-proBNP with HF risk (P=0.81).
High dietary dairy fat intake was strongly associated with
having elevated CLA% (Table 4) and was also associated with
reduced risk of HF, even after exclusion of men with MI.
However, adjustment for CLA% attenuated the association
(Table 4). We also examined the relationship between CLA%
and risk of HF stratiﬁed by dietary dairy fat intake. Because of
the smaller numbers in the lower dietary dairy intake groups,
we combined the 2 lowest dairy intake groups together to
achieve sufﬁcient numbers in the stratiﬁed analysis. The lower
risk of HF associated with elevated CLA% was only evident in
those with higher levels of dairy fat intake (Table 5). No
beneﬁt was seen in those with lower dairy intake, and a test
for interaction between CLA% and dairy fat intake and risk of
HF was signiﬁcant (P=0.03). By contrast, no interaction was
seen with frequency of beef intake (>2/week versus ≤2/
week) (P=0.51).
Discussion
In this study of older British men, there was no association
between circulating levels of CLA, relative to total fatty acids,
and incident MI, despite its adverse effects on blood lipids.
CLA% was, however, shown to be associated with a lower
risk of HF, which was independent of potential confounders
and inﬂammatory markers. The relationship between CLA%
and incident HF was, to some extent, mediated by NT-
proBNP, a marker of cardiac damage and ventricular stress,
and was only seen in those with higher dairy fat intake. Our
study adds to the growing literature on CLA and CVD further
by examining the association between circulating CLA% and a
wide range of vascular risk markers, including NT-proBNP
and incident HF, not previously examined. Dietary dairy fat
intake, which was signiﬁcantly associated with CLA%, was
not associated with incident MI, a ﬁnding that is consistent
with numerous other studies.25 However, it was associated
with a lower risk of HF, which was largely accounted for by
CLA%.
CLA and CVD Risk
CLAs are a collection of positional and geometric isomers of
linoleic acid, with the c9,t11-CLA and trans-10, cis-12-CLA
being the 2 main isomers known to possess biological
activity.3 Although numerous animal studies have shown CLA
to exert antiatherogenic properties,1–3,7 the beneﬁcial effects
of CLA on CVD risk in humans are less conclusive.7 Many
studies have shown unfavorable effects of CLA on lipoprotein
levels, similar to that of other TFAs,6 as was observed in this
study, whereas others have shown beneﬁcial or no effects.7,9
We have observed a positive association between CLA% and
blood pressure, in contrast to studies suggesting that CLA
supplementation may decrease blood pressure.3 However,
CLA% was associated with lower levels of CRP, consistent
with clinical and dietary intervention studies suggesting an
anti-inﬂammatory effect of CLA.2,3,13 Other studies, however,
have reported no association or positive associations between
CLA and inﬂammation.11,12 The c9,t11-CLA isomer is the
principal dietary form of CLA, accounting for as much as 85%
to 90% of total CLA in dairy products, and is the predominant
isomer present in human plasma.26 The trans-10, cis-12-CLA
isomer is not produced in detectable amounts naturally but is
Table 2. Spearman Partial Correlation Coefﬁcients Between
Serum CLA% and Biological Markers in All Men With No
Prevalent HF
Variable
Age
Adjusted
Age+BMI
Adjusted
Age+BMI
Adjusted*
SBP 0.04† 0.04† 0.03†
Cholesterol 0.19† 0.20† 0.19†
HDL cholesterol 0.09† 0.06† 0.07†
Glucose§ 0.05† 0.04† 0.04†
FEV1 0.01 0.01 0.01
CRP§ 0.04† 0.06† 0.05†
cTnT§ 0.007 0.007 0.002
NT-proBNP§ 0.08† 0.06† 0.08†
BMI indicates body mass index; CLA%, conjugated linoleic acid expressed as a
percentage of total fatty acids; CRP, C-reactive protein; cTnT, cardiac troponin T; FEV1,
forced expiratory volume in 1 second; HDL, high-density lipoprotein; HF, heart failure;
NT-proBNP, N-terminal pro-B-type natriuretic peptide; and SBP, systolic blood pressure.
*Excludes 381 men with prevalent myocardial infarction.
†P<0.05.
§Logarithm.
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found in larger amounts as a product of commercial CLA
synthesis. Many of the studies on the effects of CLA on
cardiovascular risk factors have focused on supplementary
CLA, which commonly consists of roughly equal portions of
c9,t11-CLA and trans-10, cis-12-CLA; it is possible that the 2
isomers may have differing effects on cardiovascular risk. This
may account for the inconsistencies seen between studies on
the effects of CLA on cardiovascular risk factors.
CLA and HF Risk
A novel ﬁnding in this study is the inverse association seen
between serum CLA% and risk of incident HF, which was not
explained by established risk factors for HF. A possible
mechanism may involve inhibition of cardiac hypertrophy.8
Animal and clinical studies have shown CLA to suppress
cardiomyocyte hypertrophy through activation of the perox-
isome proliferator activated receptor isoforms,8 which play an
important role in cardiac function and fatty acid use in the
healthy heart.27 Cardiac hypertrophy occurs in response to
aberrant stress signals (eg, neurohormonal activation, inﬂam-
mation, or cardiac injury). The ﬁndings that CLA% was
inversely associated with NT-proBNP, a marker of neurohor-
monal activation and cardiac injury, are consistent with the
suggestion that CLA inhibits cardiac hypertrophy.8 The
association between CLA% and incident HF was mediated
by NT-proBNP, suggesting that CLA may prevent the devel-
opment of cardiac hypertrophy, a major factor leading to HF.
Table 3. Incidence Rate/1000 Person-Years and Adjusted Relative HRs and 95% CIs for Incident HF by Quartiles of CLA% in Men
With No Prevalent HF
Variable
CLA% (Quartiles)
1 2 3 4
All men
N 915 960 971 960
Rate/1000 person-years (n) 8.1 (86) 7.7 (79) 7.5 (77) 5.5 (56)
HR (95% CI)
Age adjusted 1.00 0.91 (0.67–1.24) 0.88 (0.65–1.20) 0.61 (0.44–0.86)
Model 1 1.00 0.88 (0.65–1.20) 0.95 (0.70–1.31) 0.63 (0.44–0.89)
Model 2 1.00 0.89 (0.64–1.23) 0.97 (0.69–1.35) 0.64 (0.43–0.96)
Model 3 1.00 0.89 (0.64–1.24) 1.00 (0.71–1.41) 0.70 (0.47–1.05)
No MI
N 818 843 882 882
Rate/1000 person-years (n) 7.1 (69) 6.0 (56) 6.0 (57) 5.0 (47)
HR (95% CI)
Age adjusted 1.00 0.81 (0.87–1.16) 0.80 (0.56–1.14) 0.63 (0.43–0.91)
Model 1 1.00 0.82 (0.57–1.18) 0.82 (0.57–1.18) 0.67 (0.46–0.98)
Model 2 1.00 0.80 (0.55–1.16) 0.80 (0.54–1.16) 0.63 (0.41–0.98)
Model 3 1.00 0.76 (0.51–1.11) 0.83 (0.56–1.23) 0.65 (0.41–1.01)
With MI
N 97 117 89 78
Rate/1000 person-years (n) 18.4 (17) 23.4 (23) 25.6 (20) 12.4 (9)
HR (95% CI)
Age adjusted 1.00 1.22 (0.64–2.31) 1.34 (0.69–2.59) 0.63 (0.28–1.43)
Model 1 1.00 0.94 (0.47–1.87) 1.39 (0.67–2.80) 0.46 (0.18–1.15)
Model 2 1.00 1.08 (0.53–2.21) 1.76 (0.83–3.75) 0.61 (0.23–1.66)
Model 3 1.00 1.10 (0.52–2.31) 1.64 (0.76–3.67) 0.64 (0.23–1.75)
Model 1, adjusted for age, smoking, heavy drinking, social class, body mass index, high-density lipoprotein cholesterol, systolic blood pressure, atrial ﬁbrillation, left ventricular
hypertrophy, prevalent diabetes mellitus, prevalent myocardial infarction, and C-reactive protein. Model 2, adjusted for model 1 plus polyunsaturated fatty acids. Model 3, adjusted for
model 2 plus N-terminal pro-B-type natriuretic peptide. CI indicates conﬁdence interval; CLA%, conjugated linoleic acid expressed as a percentage of total fatty acids; HF, heart failure; HR,
hazard ratio; and MI, myocardial infarction.
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Although circulating c9,t11-CLA in plasma correlates
strongly with dietary intake of c9,t,11-CLA,28 CLA in humans
may not be totally determined by dietary CLA because CLA
may also reﬂect metabolism. There is evidence of conversion
to CLA of TFAs in humans.29 Vaccenic acid (VA), a major TFA
in milk fat, has been shown to be converted to rumenic acid,
an isomer of CLA, in human tissues by the D-9-desaturase
enzyme, with an average of 19% of dietary VA being
converted to c9,t11-CLA.29 VA is the only known dietary
precursor of c9,t11-CLA. We did not have measures of VA.
However, VA has not been shown to be associated with lower
risk of HF in those without MI,30 whereas CLA was shown to
be associated with reduced HF, even in men without MI. The
ﬁnding that only elevated CLA% in men with higher dietary
dairy fat intake (groups 3 and 4) was associated with reduced
risk of HF suggests that CLA derived from dairy products and
not from fatty acid metabolism is protective. Moreover, the
difference in ﬁndings between elevated CLA% and HF risk in
those with lower and those with higher dairy fat intake
suggests that it is the c9,t11- CLA isomer that accounts for
>75% of CLA in milk; this is the protective isomer, rather than
the t10,c12-CLA isomer, which accounts for <1% of CLA in
milk.26,31
The biological plausibility and inhibition of cardiac hyper-
trophy shown in animal studies and the inverse association
seen with NT-proBNP in this study, a marker of cardiac
hypertrophy, suggest that CLA derived from dairy products
may speciﬁcally be involved in the development of HF.
Although many trials of the effects of CLA supplements on
CVD risk factors have been disappointing, most have focused
on overall traditional CVD or CHD risk factors, such as lipids
and blood glucose, rather than changes in left ventricular
structure and function.
CLA and Incident CHD
In contrast to HF, we observed no association between CLA%
and development of CHD in these older men. However, one
case-control study conducted in a Costa Rican population
(average age, 58 years) showed c9,t11-CLA in adipose tissue
to be associated with lower risk of MI.14 Because c9,t11-CLA
is the predominant isomer present in human plasma, the
difference in ﬁndings may be because of the different assay
methods used or the different characteristics of the study
group.
Strengths and Limitations
Strengths and limitations of the study require consideration.
This is the ﬁrst study to examine the association between
Table 4. Incidence Rate/1000 Person-Years and Adjusted Relative HRs and 95% CIs for Incident HF According to Dietary Dairy
Fat Intake in Men With No Prevalent HF
Variable
Dairy Fat Intake
1 (Low) 2 3 4 (High)
All men 549 363 2014 806
CLA%, meanSD 0.320.15 0.330.17 0.380.16 0.450.19
Rate/1000 person-years 9.8 6.8 7.2 6.0
HR (95% CI)
Age adjusted 1.00 0.77 (0.49–1.21) 0.73 (0.54–0.99) 0.54 (0.37–0.79)
Model 1 1.00 0.87 (0.54–1.38) 0.88 (0.64–1.21) 0.71 (0.47–1.06)
Model+CLA% 1.00 0.88 (0.55–1.40) 0.92 (0.67–1.27) 0.78 (0.52–1.19)
No MI
N 452 320 1822 765
Rate/1000 person-years 8.4 5.4 5.8 5.6
HR (95% CI)
Age adjusted 1.00 0.71 (0.41–1.21) 0.69 (0.48–0.91) 0.58 (0.38–0.87)
Model 1 1.00 0.74 (0.43–1.28) 0.75 (0.52–1.08) 0.63 (0.40–0.98)
Model 1+CLA% 1.00 0.83 (0.53–1.32) 0.84 (0.62–1.15) 0.68 (0.45–1.10)
Model 1, adjusted for age, smoking, heavy drinking, body mass index, high-density lipoprotein cholesterol, systolic blood pressure, atrial ﬁbrillation, left ventricular hypertrophy, prevalent
diabetes mellitus, prevalent myocardial infarction, and C-reactive protein. 2, skimmed mik and full fat cheese or full fat milk and low fat cheese. 3, semi-skimmed milk and full fat cheese.
4, full-fat milk and high-fat cheese. Low, skimmed/semiskimmed milk and low-fat cheese. CI indicates conﬁdence interval; CLA%, serum conjugated linoleic acid expressed as a percentage
of total fatty acids; HF, heart failure; HR, hazard ratio; and MI, myocardial infarction.
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circulating CLA% and incident HF in a general population of
older men who constitute a high-risk group for CVD and HF.
The study population is socially representative of the UK
population, and follow-up rates in the British Regional Heart
Study are exceptionally high.15 However, it was based on an
older predominantly white male population of European
extraction, so that the results cannot be generalized directly
to women, younger populations, or other ethnic groups. The
current ﬁndings are based on physician-diagnosed HF, which
has yielded estimates of HF incidence consistent with those of
earlier reports.32,33 Moreover, the determinants of HF in this
study population (including obesity, NT-proBNP, lung function,
and heavy drinking)16–18,34 generally accord with prior data
and suggest that the HF outcome used was valid. However,
echocardiographic measurements were not routinely per-
formed, and we were not able to differentiate systolic and
diastolic HF. Dietary intake was assessed using an FFQ, which
has previously been validated against weighed food intakes
and serum levels in British populations,35,36 and the dietary
intake of participants was broadly comparable with those from
the National Diet and Nutrition Survey.37 However, FFQs are
more prone to measurement error compared with some other
dietary measures, and in older populations, nonresponse to
FFQ questions could have increased the chance of dietary
underreporting. The present study was based on a prospective
observational study and was not a randomized trial. We were
not able to differentiate the different CLA isomers, and we had
no measure of VA. CLA was measured using a high-spectro-
scopy NMR platform and not the standard gas chromatogra-
phy method for measuring fatty acids. However, fatty acids
composition quantiﬁed by NMR from fasting serum samples
has been shown to correlate highly with measures using gas
chromatography (correlation coefﬁcient ranging from 0.92 to
0.94),23 suggesting that the method is accurate.
Table 5. Incidence Rate/1000 Person-Years and Adjusted Relative HRs and 95% CIs for Incident HF by Quartiles of CLA%
According to Dietary Dairy Fat Intake in Men With No Prevalent HF
Variable
CLA% (Quartiles)
1 (Low) 2 3 4 (High)
Lower dairy intake
N (n) 316 (26) 258 (26) 210 (25) 128 (16)
Rate/1000 person-years 7.6 9.1 7.2 12.3
HR (95% CI)
Age adjusted 1.00 1.23 (0.71–2.13) 0.93 (0.50–1.73) 1.60 (0.87–2.95)
Model 1 1.00 1.24 (0.69–2.21) 0.98 (0.52–1.86) 1.53 (0.80–2.91)
Model 1+NT-proBNP 1.00 1.23 (0.69–2.21) 1.05 (0.54–2.04) 1.67 (0.87–3.21)
Medium dairy intake
N (n) 470 (43) 514 (49) 543 (44) 765 (26)
Rate/1000 person-years 8.6 7.5 7.5 5.0
HR (95% CI)
Age adjusted 1.00 0.90 (0.59–1.37) 0.90 (0.59–1.57) 0.55 (0.34–0.90)
Model 1 1.00 0.81 (0.53–1.26) 0.93 (0.61–1.43) 0.49 (0.29–0.81)
Model 1+NT-proBNP 1.00 0.85 (0.54–1.33) 0.94 (0.60–1.46) 0.51 (0.30–0.87)
High dairy intake
N (n) 100 (10) 169 (10) 206 (17) 331 (13)
Rate/1000 person-years 9.6 5.7 8.2 3.7
HR (95% CI)
Age adjusted 1.00 0.61 (0.26–1.48) 0.92 (0.42–2.01) 0.43 (0.19–0.98)
Model 1 1.00 0.53 (0.21–1.32) 0.86 (0.38–1.99) 0.41 (0.17–0.98)
Model 1+NT-proBNP 1.00 0.48 (0.19–1.24) 0.99 (0.42–2.55) 0.49 (0.20–1.20)
Model 1, adjusted for age, smoking, heavy drinking, body mass index, high-density lipoprotein cholesterol, systolic blood pressure, atrial ﬁbrillation, left ventricular hypertrophy, prevalent
diabetes mellitus, prevalent myocardial infarction, and C-reactive protein. High, high-fat milk and full-fat cheese. Medium, semiskimmed milk and full-fat cheese or full-fat milk and low-fat
cheese. Lower (groups 1 and 2), skimmed/semiskimmed milk and low-fat cheese or skimmed milk and full-fat cheese. CI indicates conﬁdence interval; CLA%, serum conjugated linoleic
acid expressed as a percentage of total fatty acids; HF, heart failure; HR, hazard ratio; and NT-proBNP, N-terminal pro-B-type natriuretic peptide.
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Conclusion
This study may have important implications for effective
nutritional intervention towards the prevention of HF in older
men who are at high risk of developing HF. This is the ﬁrst
study on the association between CLA% and risk of HF, and
our ﬁndings need conﬁrmation in other populations. If so,
primary intervention trials in older people at risk of HF are
needed to conﬁrm whether increasing CLA through supple-
ments or diet would reduce risk of HF.
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